CD274 and breast carcinoma: The difference is that the targets of PD1/PDL1 are TILs, and tumor progression can be promoted by inactivation of TILs (32); however, our study confirmed that CCL5/CCR5 affects breast cancer progression and the survival of breast cancer patients by affecting the Treg/CCR5+ cell ratio.